[PDF] Top 20 <p>Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization</p>

... treatment-naïve patients with RRMS who started IFN- β while attending the outpatient clinics of 5 tertiary referral centers in Cairo, Egypt in the period from November 2014 to December 2017 were invited to ... See full document

... Multiple Sclerosis (MS) is a chronic disease with an unknown cause that results in inflammation and destruction of Myelin in central nervous system ...her frequency among women is two to three times ... See full document

... in Multiple Sclerosis (ECTRIMS) meet- ing in ...117 patients with relapsing MS already on a stable dose of IFN- β ...of patients were on low-dose IFN- β 1a – 30 μ g intra- muscularly once ... See full document

... The prevalence of OAB ranges from 37 – 99% based on screening tools and assessment, 26 which is de fi ned as urgency, urge incontinence, urinary frequency, and nocturia. 27 OAB symptom severity is correlated with ... See full document

... the frequency of relapses, but not for reducing the progression of ...of multiple sclerosis requires two or more episodes of symptoms and signs, glatiramer acetate is approved for treatment after ... See full document

... for patients with RRMS and SPMS with in fl am- matory ...and frequency-dependent and early treatment was bene fi ...While interferon therapy was considered overall a safe treatment, patient support was ... See full document

... neurological patients with ...the patients at risk of dysphagia to drink ...of patients with MS to assess the frequency of dysphagia, dyspha- gia-related symptoms, 79 consecutive ... See full document

... MS patients, 40 (40%) fulfilled the current ABN criteria for stopping therapy during the ...(8%) patients met both the first two stopping criteria (two disabling relapses within a 12 month period and the ... See full document

... treated patients, 12% - 28% of IFNβ-1a SC treated patients, and 2% - 6% of IFNβ-1a IM treated pa- tients had developed NAbs ...treated patients, and in 7.5% of IFNβ-1a SC treated patients, but ... See full document

... of headache in patients with multiple sclerosis is relevant ...of headache in patients with multiple sclerosis is migraine in all its forms with a frequency ... See full document

... naïve patients, data on the effectiveness of increasing the IFNB dose in patients with breakthrough disease are ...223 patients converted from Avonex to Rebif 44, documented a 50% reduction in the ... See full document

... RRMS patients, showed that pa- tients with lower expression of MxA had a higher rate of relapses ...RRMS patients, found that patients with good clinical response to IFN showed up regulated ... See full document

... The case reports suggest that if symptoms, signs, or laboratory findings indicate possible autoimmunity in patients with MS, it is better to select GA for treatment over INF-β. The case reports demonstrate that ... See full document

... intramuscular interferon b -1a in one of its Phase III trials and demonstrated greater ...subcutaneous interferon b -1a in three clinical ...for patients with highly active ...adult patients ... See full document

... MS patients. The knowledge of correct using interferon-beta (IFN-β) and attitude toward medical care were assessed using self- reported questionnaires consisted of 25 items with validity of ... See full document

... The variables assessed in the study were compiled in a questionnaire, elaborated on and validated by an MS expert committee made up of hospital pharmacists, a neurologist, and professionals, including a nurse from FEMM ... See full document

... IFNβ, interferon beta; M, macrophage; MMP, matrix metalloproteinase; MS, multiple sclerosis; PEG, polyethylene glycol; PEG-IFNβ, pegylated interferon β; TIMP-1, tissue inhibitor of ... See full document

... A literature review in the PubMed database was car- ried out, and to our knowledge, this is the sixth case of TMA induced by IFN β . A summary of TMA case reports induced by IFN β is presented in Table 2. ... See full document

... Sander van Deventer (Amsterdam, The Netherlands) reported on developments regarding inhibition of p38 MAP kinase, in particular using the compound named SB203580. The desired effect is diminished synthesis and release of ... See full document

... MS patients tended to have a higher sensitivity to IL-23, resulting in the phosphorylation of STAT3 and ...MS patients may inherently be more responsive to IL-23, which suggests that IL-23R may be a suscep- ... See full document